1-4 of 4
Jamie K. Waselenko
Close
Sort by
Journal Articles

Fludarabine, Rituximab, and Lenalidomide in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL): A Phase I/II Trial of the Sarah Cannon Research Institute

Ian W. Flinn, MD, PhD, R. Seth Cooper, MD, Dana S. Thompson, MD, Jamie K. Waselenko, MD, James Reeves, Jr., MD, Rudolph L. Wise, MD, John D. Hainsworth, MD, Jesus G. Berdeja, MD
Journal: Blood
Blood (2012) 120 (21): 715.
https://doi.org/10.1182/blood.V120.21.715.715
Published: 2012
Journal Articles

Preliminary Results From a Phase I/II Study of Fludarabine, Rituximab, and Lenalidomide In Untreated Patients with Chronic Lymphocytic Leukemia (CLL)

Ian W. Flinn, MD, PhD, Jesus G. Berdeja, MD, Jamie K. Waselenko, MD, R. Seth Cooper, MD, Jia Bi, MD, Kent Shih, MD, Habib H. Doss, MD, Natalie Dickson, MD, Dana S. Thompson, MD, Howard A. Burris, III, MD, John D. Hainsworth, MD
Journal: Blood
Blood (2010) 116 (21): 2461.
https://doi.org/10.1182/blood.V116.21.2461.2461
Published: 2010
Journal Articles

Depsipeptide (FR901228): A Novel Therapeutic Agent With Selective, In Vitro Activity Against Human B-Cell Chronic Lymphocytic Leukemia Cells

John C. Byrd, Charlotte Shinn, Rajani Ravi, Carl R. Willis, Jamie K. Waselenko, Ian W. Flinn, Nancy A. Dawson, Michael R. Grever
Journal: Blood
Blood (1999) 94 (4): 1401–1408.
https://doi.org/10.1182/blood.V94.4.1401
Published: 1999
Journal Articles

Flavopiridol Induces Apoptosis in Chronic Lymphocytic Leukemia Cells Via Activation of Caspase-3 Without Evidence of bcl-2 Modulation or Dependence on Functional p53

John C. Byrd, Charlotte Shinn, Jamie K. Waselenko, Ephraim J. Fuchs, Teresa A. Lehman, Phuong L. Nguyen, Ian W. Flinn, Louis F. Diehl, Edward Sausville, Michael R. Grever
Journal: Blood
Blood (1998) 92 (10): 3804–3816.
https://doi.org/10.1182/blood.V92.10.3804
Published: 1998